Ixekizumab for the treatment of ankylosing spondylitis |
| |
| Authors: | Jin-Xian Huang Yung-Heng Lee |
| |
| Affiliation: | 1. Division of Rheumatology, Department of Medicine, The University of Hong Kong-Shenzhen Hospital , Shenzhen, China;2. Department of Health Services Administration, China Medical University , Taichung, Taiwan;3. Department of Public Health, China Medical University , Taichung, Taiwan;4. Department of Orthopedics, Cishan Hospital, Ministry of Health and Welfare , Kaohsiung, Taiwan;5. Department of Center for General Education, National United University , Miaoli, Taiwan |
| |
| Abstract: | ![]()
ABSTRACT Introduction Ixekizumab (IXE) is a high affinity IgG4 approved for the treatment of ankylosing spondylitis (AS). Recently, two phase III randomized clinical trials (COAST-V, COAST-W) showed significant and sustained improvements in signs and symptoms of AS as evaluated by ASAS40 response. Areas covered: The authors performed a comprehensive literature search on this topic, by a review of published articles to date. The authors introduced the structure and the mechanism of action of IXE, and critically reviewed data from clinical trials, concerning its efficacy and safety in AS.Expert opinion: IXE proved dramatic efficacy and tolerable safety in patients with AS, in particular, patients with intolerance or insufficient response to TNFi, which provides an alternative and breakthrough for the treatment options of AS. IXE might not work in AS with IBD and uveitis involvement. Patients treated with IXE should be aware of candida infection in long term application. |
| |
| Keywords: | Ixekizumab ankylosing spondylitis IL-17 treatment secukinumab tumor necrosis factor inhibitors |
|
|
